ArticleFrontiers in immunology2025
Investigation of GPR137C as a promising novel marker for the progression of prostate cancer through G4 screen and bioinformatics analyses.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- GPCRs in CAR-T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Identification of G4-regulated immune-related drug targets for prostate cancer based on G4 screen and machine learning.Frontiers in immunology · 2026Article
- G protein-coupled receptors in prostate cancer: research progress and therapeutic targets.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prostate cancer (PCa) remains the fifth leading cause of male cancer mortality, necessitating novel biomarkers and therapeutic targets. Methods: Through BG4 ChIP-seq profiling in PCa cells, we identified promoter G-quadruplex (G4) structures in prognosis-associated genes, with GPR137C exhibiting a functional G4 in its promoter. Results: This G4 structure facilitates promoter hypomethylation to activate GPR137C transcription. Moreover, GPR137C promotes tumor microenvironment remodeling by enhancing immune cell infiltration, thereby driving PCa progression. Disscussion: This study establishes promoter G4s as epigenetic regulators in PCa while proposing GPR137C as both a prognostic biomarker and a therapeutic nexus for GPCR-targeted drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.